Welcome to our dedicated page for Viridian Therapeutics SEC filings (Ticker: VRDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Viridian Therapeutics, Inc. (Nasdaq: VRDN) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Viridian is a Waltham, Massachusetts-based biopharmaceutical company focused on antibody-based medicines for serious and rare diseases, including thyroid eye disease (TED) and autoimmune conditions involving IGF‑1R, TSHR, and FcRn pathways. Its common stock is registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC under the symbol VRDN, as noted in multiple Form 8‑K filings.
Through this page, users can review current and historical Forms 8‑K in which Viridian reports material events such as clinical and regulatory milestones, collaboration and license agreements, financing transactions, and governance matters. Examples disclosed in recent 8‑K filings include public equity offerings, a royalty financing agreement, an amended credit facility, and the collaboration and license agreement with Kissei Pharmaceutical Co., Ltd. for veligrotug and VRDN‑003 in Japan. Other 8‑Ks furnish press releases reporting quarterly financial results and cash positions, providing insight into the company’s operating expenses, research and development investments, and capital resources.
Investors can also use the filings page to track capital markets activity and share-related arrangements, such as underwriting agreements for public offerings, equity incentive plan amendments, and employee stock purchase plans, all of which appear in Viridian’s current reports and proxy-related disclosures. These documents outline how the company structures its financing, equity compensation, and shareholder approvals as it advances late-stage TED programs and its FcRn inhibitor portfolio.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that highlight the key points of lengthy filings. Instead of reading entire documents line by line, users can quickly understand the main terms of material agreements, the significance of clinical and regulatory announcements, and the implications of financing transactions for Viridian’s runway and strategic plans. For deeper analysis, investors can drill down into specific filings—such as 10‑K annual reports, 10‑Q quarterly reports, and Form 4 insider transaction reports when available—to examine risk factors, detailed financial statements, and any reported insider buying or selling activity related to VRDN.
Viridian Therapeutics Chief Medical Officer Radhika Tripuraneni reported equity awards consisting of stock options and restricted stock units. She acquired stock options for 95,800 shares at an exercise price of $0.00 per share, with the grant dated March 2, 2026. These options vest in 48 equal monthly installments, conditioned on continued service. She also received 19,150 restricted stock units, each representing one share of common stock. The RSUs vest over four years, with 25% vesting on each yearly anniversary of the March 2, 2026 grant date, also subject to continued service.
VRDN submitted a Form 144 reporting a proposed sale of 1,675 common shares described in the filing as related to Restricted Stock Vesting and Compensation.
The filing also lists a prior sale of 2,272 common shares dated 12/31/2025 with an indicated value of $70,795.52.
Viridian Therapeutics details its shift toward commercialization in serious and rare autoimmune diseases, led by thyroid eye disease (TED) programs. Lead IV antibody veligrotug has completed two global phase 3 trials in active and chronic TED, with a BLA under FDA Priority Review and a PDUFA target date of June 30, 2026. Subcutaneous follow‑on antibody elegrobart is in two phase 3 REVEAL studies, with topline data expected in the first and second quarters of 2026 and an auto‑injector in development for at‑home use. Viridian is also advancing FcRn inhibitors VRDN‑006 and VRDN‑008, plus an early anti‑TSHR antibody for Graves’ disease and TED. Non‑dilutive funding includes a $70 million Japan collaboration with Kissei and a revenue participation deal with DRI Healthcare for up to $300 million tied to U.S. sales milestones.
Viridian Therapeutics reported a larger net loss in 2025 while advancing its thyroid eye disease (TED) pipeline toward potential commercialization. For 2025, total revenue was $70.8 million and net loss was $342.6 million, compared with revenue of $0.3 million and net loss of $269.9 million in 2024.
Cash, cash equivalents, and marketable securities were $874.7 million as of December 31, 2025, supporting management’s view that, together with potential milestones and anticipated commercial revenue if veligrotug and elegrobart are approved, current plans can be funded through profitability. Veligrotug’s BLA is under Priority Review with a PDUFA target date of June 30, 2026, and a European MAA was submitted in January 2026. Phase 3 elegrobart REVEAL-1 and REVEAL-2 topline data are expected in Q1 and Q2 2026, and VRDN-008 entered phase 1 with data expected in 2H 2026.
Kynam Capital Management and related reporting persons filed an amended Schedule 13G/A disclosing a passive ownership stake in Viridian Therapeutics, Inc. As of 12/31/2025, they collectively reported beneficial ownership of 1,470,541 shares of Viridian common stock, representing 1.54% of the outstanding class.
The filing shows Kynam Capital Management, LP, Kynam Capital Management GP, LLC and Yue Tang each having shared voting and shared dispositive power over these 1,470,541 shares, with no sole voting or dispositive power. The certification states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Viridian.
Viridian Therapeutics, Inc. shareholder Deep Track Capital and related parties report beneficial ownership of 2,524,833 shares of common stock, representing 2.65% of the class as of December 31, 2025. The shares are held with shared voting and shared dispositive power, and no sole voting or dispositive power.
The ownership percentage is calculated using 95,442,008 shares of Viridian common stock outstanding as of October 31, 2025, as reported in the company’s Form 10-Q. The filers certify that the securities are not held for the purpose of changing or influencing control of Viridian, consistent with a passive Schedule 13G/A Amendment No. 3 filing.
Viridian Therapeutics, Inc. insider Jennifer Tousignant, the company’s Chief Legal Officer, reported a transaction in the company’s common stock. On 12/31/2025, she disposed of 2,272 shares of Viridian common stock at a price of $31.16 per share, coded as a sale. Following this transaction, the filing lists her as beneficially owning 0 shares directly. The footnote explains that the reported shares consist of stock purchased under Viridian’s employee stock purchase plan.